TSO3 http://www.tso3.com/en/ en-ca Copyright 2008 daily TSO3 announces financial results for Q1 2009 http://www.tso3.com/en/news-events/news-tso3-announces-financial-252.php The Company posts sales growth; takes decisive steps in its development Highlights of Q1 2009 and recent weeks:  The sale of three units and accessories for total revenues of $533,488, compared to revenues of $91,147 in the first quarter of 2008 generated by the sale of accessories only;  Health Canada’s authorization for the sterilization of multi-channel flexible endoscopes and Food and Drug Administration filing for similar expanded claims;  Announced second cycle to be added to new and current base of already installed TSO3 STERIZONE® 125L sterilizers, further enhancing the technologies utility.  Election of Mr. W. Barry McDonald and Mr. Jean-François Bureau to the Company’s Board of Directors. Quebec, May 15, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) posted revenues of $533,488 during the first quarter of 2009, compared to $91,147 for the same period last year. During the first three months of the current fiscal year, the Company sold three units of its STERIZONE® 125L sterilizer and accessories, whereas it sold only accessories in the same quarter of 2008. The Company’s net loss during the first quarter of 2009 was almost $2.0 million or $0.04 per share, whereas it was $2.2 million or $0.05 per share during the same period last year. “Our sales growth in the first quarter of 2009, compared to the same period last year, is encouraging and indicates that our technology is receiving increasing support from our target clientele. Various initiatives which we have recently implemented to expand the range of medical instruments that can be processed by our STERIZONE® 125L sterilizer should further drive this trend in the coming months and strengthen our competitive position in our target markets,” said Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3. The first true alternative to ethylene oxide In recent weeks, the Company took decisive steps in its development by introducing various initiatives that are positioning TSO3’s STERIZONE® 125L sterilizer as the first true alternative to legacy ethylene oxide-based sterilization systems commonly used in hospitals, which is a toxic chemistry and an environmental pollutant. On March 31, 2009, Health Canada authorized the use of TSO3’s STERIZONE® for the sterilization of multi-channel flexible endoscopes. A submission for clearance for similar expanded claims has also been filed with the Food and Drug Administration (FDA). The Company is currently awaiting a decision on this filing. On April 30, 2009, during its Annual General Meeting, the Company also announced its decision to add a second cycle to its STERIZONE® 125L sterilizer. This new cycle, while offering the same sterilization efficacy as the current base cycle, will allow TSO3’s STERIZONE® 125L to sterilize a wider range of fragile and delicate medical instruments causing less wear and tear. TSO3 expects that its existing clients will have access to this additional cycle through the use of a field upgrade after the cycle has cleared the appropriate regulatory requirements. Later this year, the Company will file for clearance with Canadian and American regulatory authorities for approval of this new cycle currently under development. Promising initiatives “These various initiatives are highly promising for TSO3 since they permit hospitals to have a true alternative solution to ethylene oxide, a toxic process that is presently the only method of sterilizing the most delicate and complex medical instruments. Compared to ethylene oxide-based systems, our solution is more efficacious, more economical and is not a threat for employee safety and the environment. In accordance with our vision, we now have all the tools necessary to make our technology the new standard for low temperature sterilization in a hospital environment,” said Mr. Rumble. Ethylene oxide-based sterilization uses an inflammable gas that is toxic for employees and the environment. TSO3’s STERIZONE® 125L uses only oxygen, water and electricity to create a safe system for users that is highly effective and leaves no toxic residue after use. Two new appointments to the Board of Directors Furthermore, TSO3 also had the pleasure of welcoming two new members to its Board of Directors, Mr. W. Barry Mcdonald and Mr. Jean-François Bureau. They were elected as board members during TSO3's Annual General Meeting held on April 30, 2009. Mr. McDonald, who held the position of interim President and Chief Executive Officer of TSO3 in 2008, is Managing Partner and founder of McDonald & Associates, a strategic and transactional global health care advisory firm. Mr. Bureau is Senior Vice-President and Chief Financial Officer of DiagnoCure, a company specialized in the development and marketing of diagnostic tests for cancer detection. Conference call TSO3 will host a telephone conference call today, May 15, 2009 at 10:30 a.m. (ET). Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3424 (Toronto area) or the toll-free number 1-800-594-3790. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days. To view the full announcement, click here. The full financial results will soon be available in the Investor's section of our Website. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. For further information: Marc Boisjoli, Chief Financial Officer 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay 514 658-8033 ir@tso3.com The Company posts sales growth;
takes decisive steps in its development

Highlights of Q1 2009 and recent weeks:

 The sale of three units and accessories for total revenues of $533,488, compared to revenues of $91,147 in the first quarter of 2008 generated by the sale of accessories only;

 Health Canada’s authorization for the sterilization of multi-channel flexible endoscopes and Food and Drug Administration filing for similar expanded claims;

 Announced second cycle to be added to new and current base of already installed TSO3 STERIZONE® 125L sterilizers, further enhancing the technologies utility.

 Election of Mr. W. Barry McDonald and Mr. Jean-François Bureau to the Company’s Board of Directors.

Quebec, May 15, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) posted revenues of $533,488 during the first quarter of 2009, compared to $91,147 for the same period last year. During the first three months of the current fiscal year, the Company sold three units of its STERIZONE® 125L sterilizer and accessories, whereas it sold only accessories in the same quarter of 2008.

The Company’s net loss during the first quarter of 2009 was almost $2.0 million or $0.04 per share, whereas it was $2.2 million or $0.05 per share during the same period last year.

“Our sales growth in the first quarter of 2009, compared to the same period last year, is encouraging and indicates that our technology is receiving increasing support from our target clientele. Various initiatives which we have recently implemented to expand the range of medical instruments that can be processed by our STERIZONE® 125L sterilizer should further drive this trend in the coming months and strengthen our competitive position in our target markets,” said Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3.

The first true alternative to ethylene oxide

In recent weeks, the Company took decisive steps in its development by introducing various initiatives that are positioning TSO3’s STERIZONE® 125L sterilizer as the first true alternative to legacy ethylene oxide-based sterilization systems commonly used in hospitals, which is a toxic chemistry and an environmental pollutant.

On March 31, 2009, Health Canada authorized the use of TSO3’s STERIZONE® for the sterilization of multi-channel flexible endoscopes. A submission for clearance for similar expanded claims has also been filed with the Food and Drug Administration (FDA). The Company is currently awaiting a decision on this filing.

On April 30, 2009, during its Annual General Meeting, the Company also announced its decision to add a second cycle to its STERIZONE® 125L sterilizer. This new cycle, while offering the same sterilization efficacy as the current base cycle, will allow TSO3’s STERIZONE® 125L to sterilize a wider range of fragile and delicate medical instruments causing less wear and tear.

TSO3 expects that its existing clients will have access to this additional cycle through the use of a field upgrade after the cycle has cleared the appropriate regulatory requirements. Later this year, the Company will file for clearance with Canadian and American regulatory authorities for approval of this new cycle currently under development.

Promising initiatives

“These various initiatives are highly promising for TSO3 since they permit hospitals to have a true alternative solution to ethylene oxide, a toxic process that is presently the only method of sterilizing the most delicate and complex medical instruments. Compared to ethylene oxide-based systems, our solution is more efficacious, more economical and is not a threat for employee safety and the environment. In accordance with our vision, we now have all the tools necessary to make our technology the new standard for low temperature sterilization in a hospital environment,” said Mr. Rumble.

Ethylene oxide-based sterilization uses an inflammable gas that is toxic for employees and the environment. TSO3’s STERIZONE® 125L uses only oxygen, water and electricity to create a safe system for users that is highly effective and leaves no toxic residue after use.

Two new appointments to the Board of Directors

Furthermore, TSO3 also had the pleasure of welcoming two new members to its Board of Directors, Mr. W. Barry Mcdonald and Mr. Jean-François Bureau. They were elected as board members during TSO3's Annual General Meeting held on April 30, 2009. Mr. McDonald, who held the position of interim President and Chief Executive Officer of TSO3 in 2008, is Managing Partner and founder of McDonald & Associates, a strategic and transactional global health care advisory firm. Mr. Bureau is Senior Vice-President and Chief Financial Officer of DiagnoCure, a company specialized in the development and marketing of diagnostic tests for cancer detection.

Conference call

TSO3 will host a telephone conference call today, May 15, 2009 at 10:30 a.m. (ET). Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3424 (Toronto area) or the toll-free number 1-800-594-3790. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days.

To view the full announcement, click here.

The full financial results will soon be available in the Investor's section of our Website.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Source: TSO3 Inc.

For further information:

Marc Boisjoli, Chief Financial Officer
418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
514 658-8033
ir@tso3.com
]]> TSO3 announces financial results for Q1 2009 2009-05-15 11:21:15 TSO3: Conference Call and Webcast - Financial Results for Q1 2009 http://www.tso3.com/en/news-events/news-tso3-conference-call-webcast-251.php Quebec City, Quebec, Canada, May 6, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) announced today that it will report financial results for the first quarter 2009 ended March 31, 2009, on Friday, May 15, 2009. TSO3 will host a conference call at 10:30 A.M. (ET) the same day. Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3424 (Toronto area) or the toll-free number 1-800-594-3790. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. For further information: Marc Boisjoli, Chief Financial Officer 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay 514 658-8033 ir@tso3.com Quebec City, Quebec, Canada, May 6, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) announced today that it will report financial results for the first quarter 2009 ended March 31, 2009, on Friday, May 15, 2009. TSO3 will host a conference call at 10:30 A.M. (ET) the same day.

Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3424 (Toronto area) or the toll-free number 1-800-594-3790. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Source: TSO3 Inc.


For further information:

Marc Boisjoli, Chief Financial Officer
418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
514 658-8033
ir@tso3.com]]> TSO3: Conference Call and Webcast - Financial Results for Q1 2009 2009-05-06 11:41:55 TSO3 announces development of a new sterilization cycle enabling a compelling alternative to environmentally toxic ethylene oxide http://www.tso3.com/en/news-events/news-tso3-announces-development-250.php Quebec, April 30, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), announced today during the Company’s annual shareholders meeting that the Company intends to add a new sterilization cycle to the TSO3 STERIZONE® 125L Sterilizer. The new cycle which is currently under development, will enable hospitals to use the system on an expanded range of delicate medical devices. This increased utility will reduce hospital operating cost while opening additional markets for the Company. The new cycle is expected to be submitted for clearance to regulatory agencies in Canada and the United States later this year. Once cleared, this cycle will be added to all new TSO3 STERIZONE® Sterilizers shipped from the Company. In addition, the Company intends to make the cycle available to existing customers as a field upgrade with minimal disruption to current users. “Adding this new cycle will address key customer needs,” explains Mr. Rumble. “First, our customers are looking for a system that will provide low temperature sterilization for a wide array of medical devices, including the most delicate instruments without the requirement to use costly and toxic sterilizing agents. The new cycle is intended to provide efficacious sterilization without increasing wear and tear on these valuable instruments and without using toxic chemistries.” In addition to providing high sterilization efficacy and material compatibility, TSO3’s new cycle is expected to offer faster turnaround times when compared to Ethylene Oxide sterilization cycles, some of these cycles can take longer than eighteen hours to complete. Mr. Rumble said that customers are also looking for a safe and environmentally-friendly sterilization method. “One of the many strengths of our system is that we use only oxygen, water and electricity to create an ozone-based sterilization process that is safe for staff to use, highly effective, and leaves no toxic residues after cycle completion. This sharply contrasts with ethylene oxide sterilization – a commonly used low temperature method that uses a toxic, flammable gas and requires environmental and personal safety apparatus to operate. For all these reasons, our TSO3 STERIZONE® Sterilization System offers a compelling alternative to ethylene oxide.” Recently, TSO3 also received approval from Health Canada to expand the intended use of the TSO3 STERIZONE® Sterilizer to include multi-channel flexible endoscopes. “This approval and our projects under development are all focused on one primary objective – to provide our customers with solutions that meet their needs for sterile efficacy, material compatibility and timely throughput that is cost effective and environmentally safe. This is all consistent with TSO3’s vision is to create the Improved Standard in Healthcare Sterilization,” said Mr. Rumble. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The TSO3 STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. For further information: Marc Boisjoli Vice President Finance and Chief Financial Officer Tel.: 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay 514 658-8033 ir@tso3.com Quebec, April 30, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), announced today during the Company’s annual shareholders meeting that the Company intends to add a new sterilization cycle to the TSO3 STERIZONE® 125L Sterilizer. The new cycle which is currently under development, will enable hospitals to use the system on an expanded range of delicate medical devices. This increased utility will reduce hospital operating cost while opening additional markets for the Company.

The new cycle is expected to be submitted for clearance to regulatory agencies in Canada and the United States later this year. Once cleared, this cycle will be added to all new TSO3 STERIZONE® Sterilizers shipped from the Company. In addition, the Company intends to make the cycle available to existing customers as a field upgrade with minimal disruption to current users.

“Adding this new cycle will address key customer needs,” explains Mr. Rumble. “First, our customers are looking for a system that will provide low temperature sterilization for a wide array of medical devices, including the most delicate instruments without the requirement to use costly and toxic sterilizing agents. The new cycle is intended to provide efficacious sterilization without increasing wear and tear on these valuable instruments and without using toxic chemistries.”

In addition to providing high sterilization efficacy and material compatibility, TSO3’s new cycle is expected to offer faster turnaround times when compared to Ethylene Oxide sterilization cycles, some of these cycles can take longer than eighteen hours to complete.

Mr. Rumble said that customers are also looking for a safe and environmentally-friendly sterilization method. “One of the many strengths of our system is that we use only oxygen, water and electricity to create an ozone-based sterilization process that is safe for staff to use, highly effective, and leaves no toxic residues after cycle completion. This sharply contrasts with ethylene oxide sterilization – a commonly used low temperature method that uses a toxic, flammable gas and requires environmental and personal safety apparatus to operate. For all these reasons, our TSO3 STERIZONE® Sterilization System offers a compelling alternative to ethylene oxide.”

Recently, TSO3 also received approval from Health Canada to expand the intended use of the TSO3 STERIZONE® Sterilizer to include multi-channel flexible endoscopes. “This approval and our projects under development are all focused on one primary objective – to provide our customers with solutions that meet their needs for sterile efficacy, material compatibility and timely throughput that is cost effective and environmentally safe. This is all consistent with TSO3’s vision is to create the Improved Standard in Healthcare Sterilization,” said Mr. Rumble.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The TSO3 STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Source: TSO3 Inc.


For further information: Marc Boisjoli
Vice President Finance and Chief Financial Officer
Tel.: 418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
514 658-8033
ir@tso3.com

]]> TSO3 announces development of a new sterilization cycle enabling a compelling alternative to environmentally toxic ethylene oxide 2009-04-30 09:30:00 TSO3 is holding Annual Meeting of Shareholders on April 30, 2009 http://www.tso3.com/en/news-events/news-tso3-is-holding-annual-249.php Quebec, April 27, 2009 – TSO3 Inc. ("TSO3") (TSX: TOS) will hold its fiscal 2008 annual meeting of shareholders on Thursday, April 30, 2009, at 9:30 a.m. in Montreal. For those who are unable to attend in person, a webcast of the meeting and management presentation will be accessible from TSO3's website at www.tso3.com. On this occasion, Mr. Germain Carrière, Chairman of the Board of Directors of TSO3, and Mr. Ric Rumble, Company’s CEO, will provide an update on the current situation, as well as on development projects. What: TSO3’s Annual Meeting of Shareholders When: Thursday, April 30, 2009, at 9:30 a.m. Where: McCord Museum Théâtre J. Armand-Bombardier 690 Sherbrooke Street West Montreal (Québec) About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com -30- Source: TSO3 Inc. For further information: Marc Boisjoli, Chief Financial Officer (418) 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay (514) 658-8033 ir@tso3.com Quebec, April 27, 2009 – TSO3 Inc. ("TSO3") (TSX: TOS) will hold its fiscal 2008 annual meeting of shareholders on Thursday, April 30, 2009, at 9:30 a.m. in Montreal. For those who are unable to attend in person, a webcast of the meeting and management presentation will be accessible from TSO3's website at www.tso3.com.

On this occasion, Mr. Germain Carrière, Chairman of the Board of Directors of TSO3, and Mr. Ric Rumble, Company’s CEO, will provide an update on the current situation, as well as on development projects.

What: TSO3’s Annual Meeting of Shareholders

When: Thursday, April 30, 2009, at 9:30 a.m.

Where: McCord Museum
Théâtre J. Armand-Bombardier
690 Sherbrooke Street West
Montreal (Québec)


About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

-30-


Source: TSO3 Inc.

For further information:

Marc Boisjoli, Chief Financial Officer
(418) 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
(514) 658-8033
ir@tso3.com
]]> TSO3 is holding Annual Meeting of Shareholders on April 30, 2009 2009-04-27 11:10:39 TSO3 receives Health Canada’s Authorization to sterilize Multi-channel Flexible Endoscopes within its STERIZONE® Sterilization System http://www.tso3.com/en/news-events/news-tso3-receives-health-canadas-247.php The expanded indication for use opens business opportunity based on superior sterile efficacy Quebec, March 31, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”), is pleased to announce that late yesterday afternoon the Company received authorization from Health Canada’s Medical Devices Bureau to expand the field of intended use of its TSO3 STERIZONE® 125L Sterilizer, to include packaged, multi-channel flexible endoscopes, such as colonoscopes, gastroscopes, bronchoscopes, ureteroscopes and choledochoscopes. “For TSO3, this authorization is another milestone in our history and opens new doors for increased business opportunities. Healthcare facilities now have a cost effective and safe replacement solution to ethylene oxide-based sterilization – a method that poses serious risks for employee safety and the environment, for the sterilization of packaged multi-channel flexible endoscopes,” said Mr. Rumble. The Company is preparing a controlled implementation of its new indications amongst its present Canadian base of clients. “Our intent is to support the introduction of this expanded claim with clinical specialists who will work directly with our current clients to maximize the utility of their TSO3 STERIZONE® 125L Sterilizer. Every cycle run in a TSO3 STERIZONE® Sterilizer versus that of a competitive technology saves the customer money,” added Mr. Robert Mosher, VP Marketing . TSO3 has also submitted for clearance with the U.S. Food and Drug Administration (FDA) for expanded claims similar to those presented to Health Canada. “Without a doubt, the work we will accomplish in the coming months in Canada will prove highly useful in the future development of the U.S. market, for which we will follow the required clearance process as outlined by the FDA. By having a product that is capable of sterilizing multiple, packaged multi-channel flexible endoscopes TSO3 has set a new standard in healthcare sterilization, this is good for our customers and our Company,” concluded Mr. Rumble. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. For further information: Marc Boisjoli, Chief Financial Officer (418) 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay (514) 658-8033 ir@tso3.com The expanded indication for use opens business opportunity
based on superior sterile efficacy


Quebec, March 31, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”), is pleased to announce that late yesterday afternoon the Company received authorization from Health Canada’s Medical Devices Bureau to expand the field of intended use of its TSO3 STERIZONE® 125L Sterilizer, to include packaged, multi-channel flexible endoscopes, such as colonoscopes, gastroscopes, bronchoscopes, ureteroscopes and choledochoscopes.

“For TSO3, this authorization is another milestone in our history and opens new doors for increased business opportunities. Healthcare facilities now have a cost effective and safe replacement solution to ethylene oxide-based sterilization – a method that poses serious risks for employee safety and the environment, for the sterilization of packaged multi-channel flexible endoscopes,” said Mr. Rumble.

The Company is preparing a controlled implementation of its new indications amongst its present Canadian base of clients. “Our intent is to support the introduction of this expanded claim with clinical specialists who will work directly with our current clients to maximize the utility of their TSO3 STERIZONE® 125L Sterilizer. Every cycle run in a TSO3 STERIZONE® Sterilizer versus that of a competitive technology saves the customer money,” added Mr. Robert Mosher, VP Marketing .

TSO3 has also submitted for clearance with the U.S. Food and Drug Administration (FDA) for expanded claims similar to those presented to Health Canada. “Without a doubt, the work we will accomplish in the coming months in Canada will prove highly useful in the future development of the U.S. market, for which we will follow the required clearance process as outlined by the FDA. By having a product that is capable of sterilizing multiple, packaged multi-channel flexible endoscopes TSO3 has set a new standard in healthcare sterilization, this is good for our customers and our Company,” concluded Mr. Rumble.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Source: TSO3 Inc.


For further information:

Marc Boisjoli, Chief Financial Officer
(418) 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
(514) 658-8033
ir@tso3.com

]]> TSO3 receives Health Canada’s Authorization to sterilize Multi-channel Flexible Endoscopes within its STERIZONE® Sterilization System 2009-03-31 10:05:59 TSO3 discloses Results for Fourth Quarter and Fiscal 2008 http://www.tso3.com/en/news-events/news-tso3-discloses-results-fourth-246.php Additionally TSO3 outlines progress on significant endeavours including filing for enhanced claims with Health Canada and the Food and Drug Administration (FDA) Highlights of annual results of 2008 and recent months:  Filing to expand claims for the sterilization of multi-channel flexible endoscopes with Health Canada and the FDA;  Adoption of a three-year strategic plan;  Improved alignment of R&D operations with market needs;  Appointment of new Vice President, Marketing;  Continued progress with research focused in the inactivation of prions;  Sales of $381,517 during the fourth quarter for a total of $2.2 million for fiscal 2008, compared to $1.7 million in 2007, for an increase of 29.1%. Quebec, March 31, 2009 – TSO3 Inc. (“TSO3”) posted sales totalling $2.2 million for the fiscal year ended December 31, 2008, compared to $1.7 million one year earlier, an increase of 29.1%. During the year, the Company sold 13 STERIZONE® 125L Sterilizers and accessories, whereas it sold 11 sterilizers in the preceding fiscal year. In the fourth quarter, the Company sold two units with accessories, compared to four units during the same period the year before. During the 4th quarter of 2008, TSO3’s achieved sales of $381,517, as compared to $675,616 for the same period in 2007. For the year ended December 31, 2008, TSO3 recorded a net loss of $9.6 million compared to $7.9 million one year earlier. The 2008 loss includes extraordinary and non recurring expenses related to restructuring measures implemented over the last year, which amounted to more than one million dollars, or approximately $0.02 per share. Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 commented that “In terms of sales, the year 2008 certainly did not meet our expectations. However, over the last few months of the year and into 2009, we have implemented several major and promising initiatives at TSO3. In particular, these initiatives included our filing, at the beginning of March, for clearance of expanded claims with Health Canada and the FDA for the sterilization of multi-channel flexible endoscopes. This clearance, once received, combined with several other initiatives, paves the way for an exciting future for the Company. With time, this should have a favourable and key impact on our sales growth”. Claims Filings On March 10, 2009, TSO3 notified Health Canada’s Medical Devices Bureau of its intent to add multi-channel flexible endoscope sterilization to the list of uses for its low temperature sterilizer, the TSO3 STERIZONE® 125L. The Company has also submitted for clearance of expanded claims with the Food and Drug Administration (FDA) to commercialize this new application in the United States. These new intended uses when cleared by the FDA would exceed those of any other new generation low temperature sterilizing system on the market. The only other method of sterilizing packaged multi-channel endoscopes currently available on the market uses ethylene oxide, an older generation of sterilization technology that has serious employee safety and environmental issues, which is not the case for TSO3’s STERIZONE® Sterilizer. The ethylene oxide method also requires substantially greater processing time. “In the field of medical instrument sterilization, TSO3 has proprietary technology, which is able to meet the health sector’s present and future needs. As instruments become increasingly complex and refined, we are confident that our technology will be more and more recognized as the improved standard for low temperature sterilization within the medical sector. In addition to increasing its utility through claims enhancement as a result of its superior sterilization efficacy, the TSO3 STERIZONE® Sterilizer is safe to use, environmentally friendly and economical. TSO3’s technology also allows for the sterilization of more instruments per single load than other methods on the market, resulting in cost and time savings for hospitals.” added Mr. Rumble. Improved Planning and Prioritization TSO3 recently adopted a new three-year strategic plan that will enable the Company to continue its development in a targeted and systematic manner. Short and mid-term goals have been set with corresponding measurements assigned. The plan enabled the re-targeting of our development programs and greatly contributed to the recent filings with Health Canada and the FDA to expand the TSO3 STERIZONE® Sterilizer’s indications for use to include sterilization of multi-channel flexible endoscopes. This work was accomplished within the timeframe the Company had set for itself. Other measurable goals have been established concerning improved compatibility of our technology with an ever increasing number of medical devices. New Additions During the last quarter of 2008, the Company also announced the appointment of Mr. Robert (Bob) F. Mosher to the position of Vice President, Marketing. Mr. Mosher has two decades of senior management experience in the international medical sterilization and healthcare sector. Prior to this appointment, he held the position of Director, Global Product Marketing, Terminal Sterilization for Johnson & Johnson / Advanced Sterilization Products. In his new position, Mr. Mosher is responsible for identifying and developing new growth opportunities for TSO3's innovative medical instrument sterilization technology in North America and worldwide. This appointment followed that of Mr. Rumble to the position of President and Chief Executive Officer of the Company on October 6, 2008. “We have a solid team in place, a technology able to enhance customer’s outcomes and the drive to succeed. I am confident and optimistic about our ability to achieve the goals that we have set and the future of our Company,” concluded Mr. Rumble. Conference Call TSO3 will host a conference call this morning at 11:00 A.M. (ET). Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montréal area), (416) 644-3421 (Toronto area) or the toll-free number 1-800-732-1073. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's website at: www.tso3.com. The Webcast will be archived for 90 days. To view the entire release, as well as the management discussion and analysis, click here. Additionally TSO3 outlines progress on significant endeavours
including filing for enhanced claims with Health Canada and the Food and Drug Administration (FDA)


Highlights of annual results of 2008 and recent months:

 Filing to expand claims for the sterilization of multi-channel flexible endoscopes with Health Canada and the FDA;
 Adoption of a three-year strategic plan;
 Improved alignment of R&D operations with market needs;
 Appointment of new Vice President, Marketing;
 Continued progress with research focused in the inactivation of prions;
 Sales of $381,517 during the fourth quarter for a total of $2.2 million for fiscal 2008, compared to $1.7 million in 2007, for an increase of 29.1%.


Quebec, March 31, 2009 – TSO3 Inc. (“TSO3”) posted sales totalling $2.2 million for the fiscal year ended December 31, 2008, compared to $1.7 million one year earlier, an increase of 29.1%. During the year, the Company sold 13 STERIZONE® 125L Sterilizers and accessories, whereas it sold 11 sterilizers in the preceding fiscal year.

In the fourth quarter, the Company sold two units with accessories, compared to four units during the same period the year before. During the 4th quarter of 2008, TSO3’s achieved sales of $381,517, as compared to $675,616 for the same period in 2007.

For the year ended December 31, 2008, TSO3 recorded a net loss of $9.6 million compared to $7.9 million one year earlier. The 2008 loss includes extraordinary and non recurring expenses related to restructuring measures implemented over the last year, which amounted to more than one million dollars, or approximately $0.02 per share.

Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 commented that “In terms of sales, the year 2008 certainly did not meet our expectations. However, over the last few months of the year and into 2009, we have implemented several major and promising initiatives at TSO3. In particular, these initiatives included our filing, at the beginning of March, for clearance of expanded claims with Health Canada and the FDA for the sterilization of multi-channel flexible endoscopes. This clearance, once received, combined with several other initiatives, paves the way for an exciting future for the Company. With time, this should have a favourable and key impact on our sales growth”.

Claims Filings

On March 10, 2009, TSO3 notified Health Canada’s Medical Devices Bureau of its intent to add multi-channel flexible endoscope sterilization to the list of uses for its low temperature sterilizer, the TSO3 STERIZONE® 125L. The Company has also submitted for clearance of expanded claims with the Food and Drug Administration (FDA) to commercialize this new application in the United States.

These new intended uses when cleared by the FDA would exceed those of any other new generation low temperature sterilizing system on the market. The only other method of sterilizing packaged multi-channel endoscopes currently available on the market uses ethylene oxide, an older generation of sterilization technology that has serious employee safety and environmental issues, which is not the case for TSO3’s STERIZONE® Sterilizer. The ethylene oxide method also requires substantially greater processing time.

“In the field of medical instrument sterilization, TSO3 has proprietary technology, which is able to meet the health sector’s present and future needs. As instruments become increasingly complex and refined, we are confident that our technology will be more and more recognized as the improved standard for low temperature sterilization within the medical sector. In addition to increasing its utility through claims enhancement as a result of its superior sterilization efficacy, the TSO3 STERIZONE® Sterilizer is safe to use, environmentally friendly and economical. TSO3’s technology also allows for the sterilization of more instruments per single load than other methods on the market, resulting in cost and time savings for hospitals.” added Mr. Rumble.

Improved Planning and Prioritization

TSO3 recently adopted a new three-year strategic plan that will enable the Company to continue its development in a targeted and systematic manner. Short and mid-term goals have been set with corresponding measurements assigned. The plan enabled the re-targeting of our development programs and greatly contributed to the recent filings with Health Canada and the FDA to expand the TSO3 STERIZONE® Sterilizer’s indications for use to include sterilization of multi-channel flexible endoscopes. This work was accomplished within the timeframe the Company had set for itself. Other measurable goals have been established concerning improved compatibility of our technology with an ever increasing number of medical devices.

New Additions

During the last quarter of 2008, the Company also announced the appointment of Mr. Robert (Bob) F. Mosher to the position of Vice President, Marketing. Mr. Mosher has two decades of senior management experience in the international medical sterilization and healthcare sector. Prior to this appointment, he held the position of Director, Global Product Marketing, Terminal Sterilization for Johnson & Johnson / Advanced Sterilization Products. In his new position, Mr. Mosher is responsible for identifying and developing new growth opportunities for TSO3's innovative medical instrument sterilization technology in North America and worldwide.

This appointment followed that of Mr. Rumble to the position of President and Chief Executive Officer of the Company on October 6, 2008. “We have a solid team in place, a technology able to enhance customer’s outcomes and the drive to succeed. I am confident and optimistic about our ability to achieve the goals that we have set and the future of our Company,” concluded Mr. Rumble.

Conference Call

TSO3 will host a conference call this morning at 11:00 A.M. (ET). Analysts and institutional investors are invited to participate. The numbers to dial for access are (514) 807-8791 (Montréal area), (416) 644-3421 (Toronto area) or the toll-free number 1-800-732-1073. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's website at: www.tso3.com. The Webcast will be archived for 90 days.

To view the entire release, as well as the management discussion and analysis, click here.
]]> TSO3 discloses Results for Fourth Quarter and Fiscal 2008 2009-03-31 09:19:50 TSO3: Conference call and Webcast - Q4 and Annual financial results http://www.tso3.com/en/news-events/news-tso3-conference-call-webcast-245.php Quebec City, Quebec, Canada, March 19, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) today announced that it will report the Company’s Q4 and annual financial results ended December 31, 2008, on Tuesday, March 31, 2009. TSO3 will host a conference call at 11:00 A.M. (ET) the same day. Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3421 (Toronto area) or the toll-free number 1-800-732-1073. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. For further information: Marc Boisjoli Vice President Finance and Chief Financial Officer Tel.: 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay, Tremblay Strategic Communications 514 658-8033 ir@tso3.com Quebec City, Quebec, Canada, March 19, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) today announced that it will report the Company’s Q4 and annual financial results ended December 31, 2008, on Tuesday, March 31, 2009. TSO3 will host a conference call at 11:00 A.M. (ET) the same day.

Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3421 (Toronto area) or the toll-free number 1-800-732-1073. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3 STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-


Source: TSO3 Inc.

For further information: Marc Boisjoli
Vice President Finance and Chief Financial Officer
Tel.: 418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay,
Tremblay Strategic Communications
514 658-8033
ir@tso3.com

]]> TSO3: Conference call and Webcast - Q4 and Annual financial results 2009-03-19 11:45:24 TSO3 announces Health Canada and Food and Drug Administration (FDA) Filings for Sterilization of Complex and Multi-channel Flexible Endoscopes http://www.tso3.com/en/news-events/news-tso3-announces-health-canada-244.php Quebec, March 10, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce that the Company has notified Health Canada’s Medical Devices Bureau of its intent to commercialize its products with expanded claims of sterile efficacy for multi-channel flexible endoscopes. In addition to filing with Health Canada, TSO3 has submitted for clearance with the Food and Drug Administration (FDA) expanded claims for its low temperature STERIZONE® 125L Sterilizer. The Company has collected significant scientific data to document its proprietary technology’s sterile efficacy across a broader range of surgical instruments. This data is in support of the Company’s belief that its technology is capable of sterilizing packaged single and multi-channel flexible endoscopes. The only other method of sterilizing packaged multi-channel endoscopes currently available on the market uses ethylene oxide, an older generation sterilization method that has serious employee safety and environmental issues and requires substantially greater processing time. The TSO3 STERIZONE® Sterilizer is non-toxic for the environment and safe to use for the employees who operate the unit. “For TSO3, these filings mark a milestone in improved product utility based on our technology. These new intended uses when cleared would exceed those of any other new generation low temperature sterilizing system. Our proprietary technology can sterilize the most complex instruments and we can process more of these instruments in a single load when compared to competitive systems. Flexible endoscopes are routinely and increasingly used in a variety of diagnostic and surgical procedures. Enhancing the utility of our sterilizer to process these complex medical devices increases value while reducing hospital sterilization cost,” says Mr. Rumble. The STERIZONE® 125L Sterilizer has previously received FDA clearance to sterilize a variety of heat and moisture sensitive instruments and is in use by hospitals in North America. This safe, environmentally friendly system uses water, oxygen and electricity to produce ozone – the system’s sterilizing agent. The notice to Health Canada’s Medical Devices Bureau and new FDA filing covers sterilization of complex and multiple channel endoscopes such as colonoscopes, gastroscopes, bronchoscopes, ureteroscopes and choledochoscopes. Dynamic Sterilant Delivery Process® “What distinguishes TSO3’s STERIZONE® Sterilizer from other medical sterilization methods is our proprietary Dynamic Sterilant Delivery Process®,” explains Mr. Simon Robitaille, Chief Scientific Officer and Co-Founder of TSO3. “TSO3’s technology produces the sterilizing agent (ozone) on site. This process enables precise sterilant dosing throughout the entire sterilizing chamber, enabling the system to sterilize the most complex medical devices. Other new generation low temperature sterilization processes available on the market use a premeasured quantity of chemistry and rely on its diffusion to reach all surfaces within the chamber. This limits the complexity and number of instruments that can be sterilized in a single load,” says Mr. Robitaille. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. For further information: Marc Boisjoli Vice President Finance and Chief Financial Officer Tel.: 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay, Tremblay Strategic Communications 514 658-8033 ir@tso3.com Quebec, March 10, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce that the Company has notified Health Canada’s Medical Devices Bureau of its intent to commercialize its products with expanded claims of sterile efficacy for multi-channel flexible endoscopes. In addition to filing with Health Canada, TSO3 has submitted for clearance with the Food and Drug Administration (FDA) expanded claims for its low temperature STERIZONE® 125L Sterilizer. The Company has collected significant scientific data to document its proprietary technology’s sterile efficacy across a broader range of surgical instruments. This data is in support of the Company’s belief that its technology is capable of sterilizing packaged single and multi-channel flexible endoscopes. The only other method of sterilizing packaged multi-channel endoscopes currently available on the market uses ethylene oxide, an older generation sterilization method that has serious employee safety and environmental issues and requires substantially greater processing time. The TSO3 STERIZONE® Sterilizer is non-toxic for the environment and safe to use for the employees who operate the unit.

“For TSO3, these filings mark a milestone in improved product utility based on our technology. These new intended uses when cleared would exceed those of any other new generation low temperature sterilizing system. Our proprietary technology can sterilize the most complex instruments and we can process more of these instruments in a single load when compared to competitive systems. Flexible endoscopes are routinely and increasingly used in a variety of diagnostic and surgical procedures. Enhancing the utility of our sterilizer to process these complex medical devices increases value while reducing hospital sterilization cost,” says Mr. Rumble.

The STERIZONE® 125L Sterilizer has previously received FDA clearance to sterilize a variety of heat and moisture sensitive instruments and is in use by hospitals in North America. This safe, environmentally friendly system uses water, oxygen and electricity to produce ozone – the system’s sterilizing agent. The notice to Health Canada’s Medical Devices Bureau and new FDA filing covers sterilization of complex and multiple channel endoscopes such as colonoscopes, gastroscopes, bronchoscopes, ureteroscopes and choledochoscopes.


Dynamic Sterilant Delivery Process®

“What distinguishes TSO3’s STERIZONE® Sterilizer from other medical sterilization methods is our proprietary Dynamic Sterilant Delivery Process®,” explains Mr. Simon Robitaille, Chief Scientific Officer and Co-Founder of TSO3. “TSO3’s technology produces the sterilizing agent (ozone) on site. This process enables precise sterilant dosing throughout the entire sterilizing chamber, enabling the system to sterilize the most complex medical devices. Other new generation low temperature sterilization processes available on the market use a premeasured quantity of chemistry and rely on its diffusion to reach all surfaces within the chamber. This limits the complexity and number of instruments that can be sterilized in a single load,” says Mr. Robitaille.


About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3 STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-


Source: TSO3 Inc.


For further information: Marc Boisjoli
Vice President Finance and Chief Financial Officer
Tel.: 418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay,
Tremblay Strategic Communications
514 658-8033
ir@tso3.com

]]> TSO3 announces Health Canada and Food and Drug Administration (FDA) Filings for Sterilization of Complex and Multi-channel Flexible Endoscopes 2009-03-10 09:54:08 TSO3 to deliver presentation on prion sterilization research to experts at meeting hosted by France’s Health Products Safety Agency (Afssaps) http://www.tso3.com/en/news-events/news-tso3-deliver-presentation-243.php The Company will outline the latest data based on studies carried out by the Health Protection Agency of the United Kingdom and sponsored by the Department of Health on the effectiveness of its Ozone sterilization technology to eliminate prion infection. Quebec, January 12, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce that the Company will be presenting data to France’s experts on prion inactivation methods for reusable medical devices. The Company will disclose results of ongoing research pertaining to the use of its proprietary ozone sterilization technology as a method for prion inactivation. This research project, sponsored by the Department of Health of the United Kingdom and contracted out to the Health Protection Agency, uses the TSO3 Sterizone® 125L Ozone sterilization system to determine the effectiveness of the technology in eliminating prion infection on medical instruments. The new data supports previous statements made in January 2008 that the Sterizone® 125L process shows promise as a technology which could be used to reduce the risk of prion contamination. Additional confirmation studies are still in progress and the Company expects results from these studies in the coming months. The meeting, hosted by the French Health Products Safety Agency (Afssaps), will be held January 13th in Paris, France. Simon Robitaille, Chief Scientific Officer of TSO3, will be delivering the presentation on behalf of the Company. “This meeting is part of a process aimed at helping France’s Afssaps establish a standard methodology for evaluating prion decontamination technologies. Prions are abnormal proteins linked to Variant Creutzfeldt-Jakob disease (vCJD). The goal of the meeting is to allow leading experts, such as university-based scientists and hospital-based health professionals, to exchange information on ways to compare the efficacy of different technologies to one common standard,” said Mr. Robitaille. “This invitation demonstrates the level of recognition that our science is raising in the international health safety field. I look forward to outlining our project to these experts who have shown such an interest in our work,” he added. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the Sterizone® 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The Sterizone® 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source : TSO3 Inc. For further information: Marc Boisjoli Chief Financial Officer Tel.: 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay, HKDP, Tel.: 514 395-0375, ext. 234 ir@tso3.com The Company will outline the latest data based on studies carried out by the Health Protection Agency of the United Kingdom and sponsored by the Department of Health
on the effectiveness of its Ozone sterilization technology to eliminate prion infection.

Quebec, January 12, 2009 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce that the Company will be presenting data to France’s experts on prion inactivation methods for reusable medical devices. The Company will disclose results of ongoing research pertaining to the use of its proprietary ozone sterilization technology as a method for prion inactivation. This research project, sponsored by the Department of Health of the United Kingdom and contracted out to the Health Protection Agency, uses the TSO3 Sterizone® 125L Ozone sterilization system to determine the effectiveness of the technology in eliminating prion infection on medical instruments.

The new data supports previous statements made in January 2008 that the Sterizone® 125L process shows promise as a technology which could be used to reduce the risk of prion contamination. Additional confirmation studies are still in progress and the Company expects results from these studies in the coming months. The meeting, hosted by the French Health Products Safety Agency (Afssaps), will be held January 13th in Paris, France. Simon Robitaille, Chief Scientific Officer of TSO3, will be delivering the presentation on behalf of the Company.

“This meeting is part of a process aimed at helping France’s Afssaps establish a standard methodology for evaluating prion decontamination technologies. Prions are abnormal proteins linked to Variant Creutzfeldt-Jakob disease (vCJD). The goal of the meeting is to allow leading experts, such as university-based scientists and hospital-based health professionals, to exchange information on ways to compare the efficacy of different technologies to one common standard,” said Mr. Robitaille. “This invitation demonstrates the level of recognition that our science is raising in the international health safety field. I look forward to outlining our project to these experts who have shown such an interest in our work,” he added.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the Sterizone® 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The Sterizone® 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-


Source : TSO3 Inc.


For further information: Marc Boisjoli
Chief Financial Officer
Tel.: 418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay, HKDP,
Tel.: 514 395-0375, ext. 234
ir@tso3.com

]]> TSO3 to deliver presentation on prion sterilization research to experts at meeting hosted by France’s Health Products Safety Agency (Afssaps) 2009-01-12 13:30:38 TSO3 appoints Robert F. Mosher as Vice-President, Marketing http://www.tso3.com/en/news-events/news-tso3-appoints-robert-f-mosher-242.php Mr. Mosher has two decades of international senior management experience in healthcare sector marketing and business start-up and turnarounds Quebec, December 3, 2008 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce the appointment of Mr. Robert (Bob) F. Mosher to the position of Vice-President, Marketing. The appointment is effective January 1,2009. Mr. Mosher has two decades of senior management experience in the international medical sterilization and healthcare sector. Prior to this appointment, he held the position of Director, Global Product Marketing, Terminal Sterilization for Johnson & Johnson/Advanced Sterilization Products. “In his new position, Bob will be responsible for identifying and developing new growth opportunities for TSO3’s innovative medical instrument sterilization technology in North America and worldwide,” said Mr. Rumble. “We anticipate that his extensive experience in the global healthcare sterilization sector and proven skills in product and brand development will greatly contribute to the Company’s future. Bob brings high level market skill that will be very valuable in the deployment of our business development strategy”. One of Mr. Mosher’s main priorities as the new Vice-President, Marketing, will be to head the Company’s marketing efforts for its patented Sterizone® 125L Ozone Sterilizer. This innovative product is a safe, economical and environmentally friendly alternative to other low temperature sterilization methods widely in use at many hospitals. “I am very happy to join the talented and dedicated TSO3 team and am highly enthusiastic about the commercial potential of the Sterizone® 125L Ozone Sterilizer,” said Mr. Mosher. “We intent to support the Company’s development through the implementation of a well targeted marketing strategy, combined with defining and commercializing increased applications of the existing technology platform. These initiatives should have a positive impact on our results, by reducing the sales cycle and opening new market opportunities. This should also increase awareness about our technology’s quality and competitive advantages within the healthcare sector.” Robert F. Mosher has an MBA, Marketing and a Bachelor of Science degree, Psychology/Business from Saint Louis University in Missouri. For twenty years he has held a range of management positions in the healthcare sector. These previous positions include: Director, Global Product Marketing, Terminal Sterilization for Johnson & Johnson/Advanced Sterilization Products; Vice President, Healthcare Consumables and Vice President, Intercontinental Commercial Operations with STERIS Corporation; Director of Marketing, Europe, Middle East and Africa for Bausch & Lomb Surgical Inc.; and Director of Marketing for Storz Ophthalmics Inc. TSO3 is also announcing that Ms Ann Hewitt has left her role as Vice President, Global Sales. “I would like to thank Ann for her contribution to TSO3’s development and wish her much success in her future endeavours,” said Mr. Rumble. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the Sterizone® 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The Sterizone® 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. For more information about TSO3, visit the Company's Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source : TSO3 Inc. For further information: Marc Boisjoli Vice President Finance and Chief Financial Officer Tel.: 418 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay, HKDP, Tel.: 514 395-0375, ext. 234 ir@tso3.com Mr. Mosher has two decades of international senior management experience in healthcare sector marketing and business start-up and turnarounds

Quebec, December 3, 2008 – Mr. R.M. (Ric) Rumble, President and Chief Executive Officer of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce the appointment of Mr. Robert (Bob) F. Mosher to the position of Vice-President, Marketing. The appointment is effective January 1,2009. Mr. Mosher has two decades of senior management experience in the international medical sterilization and healthcare sector. Prior to this appointment, he held the position of Director, Global Product Marketing, Terminal Sterilization for Johnson & Johnson/Advanced Sterilization Products.

“In his new position, Bob will be responsible for identifying and developing new growth opportunities for TSO3’s innovative medical instrument sterilization technology in North America and worldwide,” said Mr. Rumble. “We anticipate that his extensive experience in the global healthcare sterilization sector and proven skills in product and brand development will greatly contribute to the Company’s future. Bob brings high level market skill that will be very valuable in the deployment of our business development strategy”.

One of Mr. Mosher’s main priorities as the new Vice-President, Marketing, will be to head the Company’s marketing efforts for its patented Sterizone® 125L Ozone Sterilizer. This innovative product is a safe, economical and environmentally friendly alternative to other low temperature sterilization methods widely in use at many hospitals.

“I am very happy to join the talented and dedicated TSO3 team and am highly enthusiastic about the commercial potential of the Sterizone® 125L Ozone Sterilizer,” said Mr. Mosher. “We intent to support the Company’s development through the implementation of a well targeted marketing strategy, combined with defining and commercializing increased applications of the existing technology platform. These initiatives should have a positive impact on our results, by reducing the sales cycle and opening new market opportunities. This should also increase awareness about our technology’s quality and competitive advantages within the healthcare sector.”

Robert F. Mosher has an MBA, Marketing and a Bachelor of Science degree, Psychology/Business from Saint Louis University in Missouri. For twenty years he has held a range of management positions in the healthcare sector. These previous positions include: Director, Global Product Marketing, Terminal Sterilization for Johnson & Johnson/Advanced Sterilization Products; Vice President, Healthcare Consumables and Vice President, Intercontinental Commercial Operations with STERIS Corporation; Director of Marketing, Europe, Middle East and Africa for Bausch & Lomb Surgical Inc.; and Director of Marketing for Storz Ophthalmics Inc.

TSO3 is also announcing that Ms Ann Hewitt has left her role as Vice President, Global Sales. “I would like to thank Ann for her contribution to TSO3’s development and wish her much success in her future endeavours,” said Mr. Rumble.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the Sterizone® 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment.

In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

The Sterizone® 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-


Source : TSO3 Inc.


For further information: Marc Boisjoli
Vice President Finance and Chief Financial Officer
Tel.: 418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay, HKDP,
Tel.: 514 395-0375, ext. 234
ir@tso3.com]]> TSO3 appoints Robert F. Mosher as Vice-President, Marketing 2008-12-03 08:57:12